0.000USD0.000Pre-market 07/24, 09:30 (ET)
162.50BMarket Cap
17.65P/E TTM
Key Figures
129.220Open
131.070High
6.30MVolume
17.65P/E TTM
13.44P/E Dynamic
3.190Dividend TTM
0.51%Turnover Ratio
130.340Prev. Close
127.610Low
649.10MTurnover
338.55P/E Static
6.91P/B
2.44%Div Yield TTM
16.35%ROA
157.29052wk High
0.98Volume Ratio
480.00MNet Profit
1.24BShares
7.4127EPS TTM
0.34Beta
43.19%ROE
104.46052wk Low
2.65%Amplitude
79.24%Gross Margin
162.50BMarket Cap
2.69Reward/Risk
1.54%Risk Rate
Currency: USD Updated: 2026-07-23 Key Insights
Gilead Sciences Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 5 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 158.09.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Gilead Sciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Gilead Sciences Inc Highlights
StrengthsRisks
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Gilead Sciences Inc Info
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.
Ticker SymbolGILD
CompanyGilead Sciences Inc
CEOO'Day (Daniel P)
Websitehttps://www.gilead.com/
Shareholders
FAQs
What is the current price of Gilead Sciences Inc (GILD)?
The current price of Gilead Sciences Inc (GILD) is 130.84.
What is the symbol of Gilead Sciences Inc?
The ticker symbol of Gilead Sciences Inc is GILD.
What is the 52-week high of Gilead Sciences Inc?
The 52-week high of Gilead Sciences Inc is 157.29.
What is the 52-week low of Gilead Sciences Inc?
The 52-week low of Gilead Sciences Inc is 104.46.
What is the market capitalization of Gilead Sciences Inc?
The market capitalization of Gilead Sciences Inc is 162.50B.
Is Gilead Sciences Inc (GILD) currently rated as Buy, Hold, or Sell?
According to analysts, Gilead Sciences Inc (GILD) has an overall rating of Buy, with a price target of 158.09.
What is the Earnings Per Share (EPS TTM) of Gilead Sciences Inc (GILD)?
The Earnings Per Share (EPS TTM) of Gilead Sciences Inc (GILD) is 6.84.
